Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ATXI

DatePrice TargetRatingAnalyst
More analyst ratings

$ATXI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

    MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. "We have generated considerable momentum this past quarter in advancing our pipeline of innovative treatments for neurologic diseases," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. "AJ201 is a potential best-in-class asset that would bring a disease-modifying therapeutic option to patients with significant unmet m

    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

    MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET. The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here. About Avenue TherapeuticsAvenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focus

    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Avenue Therapeutics to Participate in Upcoming Investor Conferences

    MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Location: New YorkFormat: Company Presentation and 1x1 Meetings Lake Street Capital Markets BIG8 ConferenceDate: Thursday, September 12, 2024Location: New YorkFormat: 1x1 Meetings The H.C. Wainwright

    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ATXI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ATXI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ATXI
SEC Filings

See more

$ATXI
Leadership Updates

Live Leadership Updates

See more
  • Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

    MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and chronic kidney disease, today announced the appointments of Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer and Vibeke Strand, M.D., MACR, FACP, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University, to its Board of Directors. Lindsay A. Rosenwald, M.D., Fortress' Chairman and Chief Executive Officer and Board Member of Urica, said, "We ar

    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ATXI
Financials

Live finance-specific insights

See more
  • Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

    MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA"), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome co

    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

    Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi

    $ATXI
    $CKPT
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ATXI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more